PerkinElmer Announces Production and Availability of Multi-analyte Respiratory Panel in Finland for COVID-19 and Flu Testing
24 November 2020 - 09:00AM
Business Wire
CE marked assay enables the differential
diagnosis of SARS-CoV-2, influenza A and B viruses, and RSV in a
single test
PerkinElmer, Inc., a global leader committed to innovating for a
healthier world, today announced its PKamp™ Respiratory SARS-CoV-2
RT-PCR Panel is now being manufactured at the Company’s Turku,
Finland site for distribution in Europe. This multi-analyte
respiratory panel received CE-IVD approval in October 2020. The
assay enables the differential diagnosis of SARS-CoV-2, influenza A
viruses, influenza B viruses and respiratory syncytial virus (RSV)
in a single test.
Rather than running multiple tests on samples, the PKamp
Respiratory SARS-CoV-2 RT-PCR Panel is designed to conserve
resources by testing a single nasopharyngeal swab sample collected
from individuals suspected of respiratory viral infection
consistent with COVID-19, the flu and RSV. This multi-analyte panel
is designed to be used with PerkinElmer’s automated viral nucleic
extractor to detect smaller amounts of viral material in
samples.
“As cases of COVID-19 continue to increase globally, the
availability of this multi-analyte respiratory panel in Finland
comes just in time to help healthcare providers and laboratories
manage testing demand,” said Petri Kallio, managing director and
site leader of PerkinElmer’s Turku location. “COVID-19 and the
common flu can present similar symptoms in some individuals, so
this test should help detect and diagnose viruses associated with
both conditions and ensure individuals are given appropriate
treatment when needed.”
Earlier this year, PerkinElmer’s Turku site also launched a dry
blood spot (DBS) based test for SARS-CoV-2 IgG using its
GSP®/DELFIA® platform, enabling processing of up to 5,000 samples
per day. Serological tests like this one detect antibodies in the
blood that are formed after an immune reaction to a pathogen has
taken place. Serological tests will play an increasingly important
role in large scale population screening as COVID-19 vaccines and
vaccination programs are introduced, as they can aid in identifying
individuals with an adaptive immune response to SARS-CoV-2,
indicating recent or prior infection.
The PerkinElmer Turku site has grown production and delivery
operations of COVID-19 related solutions significantly. To date,
more than 12.4 million PerkinElmer® SARS-CoV-2 Real-time RT-PCR
kits have been delivered from this site to testing facilities in
countries accepting CE mark.
PerkinElmer is actively working with specialty and reference
diagnostic labs, clinics, hospitals, pharmaceutical and
biopharmaceutical labs, academia, and governmental and research
institutes to battle the pandemic. PerkinElmer’s comprehensive
SARS-CoV-2 offerings span high throughput RNA extraction, RT-PCR,
automation, ELISA, chemiluminescence,
time-resolved fluorescence and lateral flow based serology
testing.
About PerkinElmer
PerkinElmer enables scientists, researchers, and clinicians to
address their most critical challenges across science and
healthcare. With a mission focused on innovating for a healthier
world, we deliver unique solutions to serve the diagnostics, life
sciences, food, and applied markets. We strategically partner with
customers to enable earlier and more accurate insights supported by
deep market knowledge and technical expertise. Our dedicated team
of about 13,000 employees worldwide is passionate about helping
customers work to create healthier families, improve the quality of
life, and sustain the wellbeing and longevity of people globally.
The Company reported revenue of approximately $2.9 billion in 2019,
serves customers in 190 countries, and is a component of the
S&P 500 index. Additional information is available through
1-877-PKI-NYSE, or at www.perkinelmer.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201124005122/en/
Media Relations: Chet Murray (781) 663-5719
chet.murray@perkinlelmer.com